

UNCLASSIFIED

AD NUMBER

AD351962

CLASSIFICATION CHANGES

TO: unclassified

FROM: confidential

LIMITATION CHANGES

TO:
Approved for public release, distribution unlimited

FROM:
Distribution authorized to U.S. Gov't. agencies and their contractors; Administrative/Operational Use; JUL 1964. Other requests shall be referred to Chemical Research and Development Labs., Edgewood Arsenal, MD.

AUTHORITY

EA D/A ltr, 17 Sep 1975; EA per DTIC form 55

THIS PAGE IS UNCLASSIFIED

UNCLASSIFIED

AD. 351962

CLASSIFICATION CHANGED
TO: ~~UNCLASSIFIED~~
FROM: ~~CONFIDENTIAL~~
AUTHORITY:

EA. D/A
Noted
17 Sept 75

UNCLASSIFIED

NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

NOTICE:

THIS DOCUMENT CONTAINS INFORMATION
AFFECTING THE NATIONAL DEFENSE OF
THE UNITED STATES WITHIN THE MEAN-
ING OF THE ESPIONAGE LAWS, TITLE 18,
U.S.C., SECTIONS 793 and 794. THE
TRANSMISSION OR THE REVELATION OF
ITS CONTENTS IN ANY MANNER TO AN
UNAUTHORIZED PERSON IS PROHIBITED
BY LAW.

CONFIDENTIAL

AL

**U. S. Army
Chemical Research and Development Laboratories
Technical Report**

ly

port

CRDLR 3226

The Human Assessment of EA 1729 and
EA 3528 by the Inhalation Route (U)

EA 1729 and
on Route (U)

by

James S. Ketchum
George K. Aghajanian
Oscar H. L. Ding

rum
ijanian
ing

July 1964

4



EDGEMOUL ARSENAL, MD

VAL, MD

GROUP 4

DOWNGRADED AT 3 YEAR INTERVALS;
DECLASSIFIED AFTER 12 YEARS

EAR INTERVALS;
12 YEARS

CONFIDENTIAL

CONFIDENTIAL

02185

351962

Defense Documentation Center Availability Notice

Qualified requesters may obtain copies of this report from
Headquarters, Defense Documentation Center, Attn: TISIA-2,
Cameron Station, Alexandria, Virginia.

CONFIDENTIAL

July 1964

CRDLR 3226


**THE HUMAN ASSESSMENT OF EA 1729 AND
EA 3528 BY THE INHALATION ROUTE (U)**

by

James S. Ketchum
George K. Aghajanian
Oscar H. L. Bing

Clinical Research Division

Recommending Approval:



JOSEPH R. BLAIR

Colonel, MC
Director of Medical Research

Approved:



S. D. SILVER
Technical Director

U. S. Army Edgewood Arsenal
CHEMICAL RESEARCH AND DEVELOPMENT LABORATORIES
Edgewood Arsenal, Maryland

CONFIDENTIAL

UNCLASSIFIED

(U)

FOREWORD

This work was conducted under Project 1C522301A079, Non-Defense Medical Aspects of Chemical Agents (U). The work was started in March 1963 and completed in April 1964.

Acknowledgments

The assistance of the Aerosol Branch and the Clinical Investigation Branch is gratefully acknowledged.

Notices

This document contains information affecting the national defense of the United States within the meaning of the Espionage Laws, Title 18, U. S. C., sections 793 and 794. The transmission or the revelation of its contents in any manner to an unauthorized person is prohibited by law.

Reproduction of this document in whole or in part is prohibited except with permission of the issuing office; however, DDC is authorized to reproduce this document for U. S. Governmental purposes.

Disposition

When this document has served its purpose, DESTROY it in accordance with AR 380-5. DO NOT return the document to U. S. Army Edgewood Arsenal Chemical Research and Development Laboratories.

UNCLASSIFIED

CONFIDENTIAL

(C)

DIGEST

A study of the inhalation effectiveness of agent EA 1729 (d-lysergic acid diethylamide) and its maleate salt was conducted in which retained doses ranging from 0.3 to 7.8 $\mu\text{g}/\text{kg}$ were administered to 60 military volunteers.

The ED50 for EA 1729 by the inhalation route is 5.8 (2.5 to 13.5) $\mu\text{g}/\text{kg}$ retained dose. The ECT50 is 55 (34 to 90) mg min/cu m, calculated at a minute volume of 10 liters. The ED50 and ECT50 for the maleate salt would be 1/3 greater on a formula weight basis, i. e., 7.7 $\mu\text{g}/\text{kg}$ and 73 mg min/cu m, respectively.

Onset time for the effective aerosol dose is about 15 min, peak time about 1-1/2 hr, and partial recovery time about 5-1/2 hr. Full recovery requires at least 12 hr.

The safety factor in man cannot be stated with certainty. If man resembles most other animals in his toxicological response, the ratio of lethal to effective dose would be very high; however, there is no direct information about lethality in man.

If a correction is made for differences in formula weight, the effectiveness of the maleate and free base forms of the agent by inhalation is roughly the same.

There is a tendency to cough during inhalation of the maleate at higher concentrations, but in the few instances in which this occurred, there was no change in the retained dose.

By the aerosol dissemination technique employed, it was shown that the effectiveness of the aerosol route is 0.25 to 0.30 that of the oral or intravenous routes.

Prior exposure to the agent does not significantly influence the numerical facility performance decrement observed when an equivalent dose is given 2 weeks later.

CONFIDENTIAL

UNCLASSIFIED

(U)

CONTENTS

| | <u>Page</u> |
|--|-------------|
| I. INTRODUCTION | 5 |
| II. METHODS..... | 11 |
| A. Selection and Management of Volunteers..... | 11 |
| B. Description of Measurements Used | 12 |
| C. Technique of Exposure | 17 |
| D. Tabulation of Data | 17 |
| III. RESULTS | 19 |
| A. What is the ED50 and the ECT50 for LSD25 by the Inhalation Route? | 19 |
| B. What are the Onset Times, Peak Times and Durations of Action of the Effective Inhalation Dose? | 19 |
| C. What is the Estimated Safety Factor for the Agent?..... | 22 |
| D. Is There Any Difference in Potency Between the Free Base and the Maleate on a Molecule-for-Molecule Basis? | 22 |
| E. Is the Coughing Tendency Observed Earlier With the Maleate a Consistent Finding and Does It Have Practical Significance?..... | 30 |
| F. What is the Relative Effectiveness of the Inhalation Route, Compared to the Oral and Intravenous Routes?..... | 30 |
| G. Does the Response to a Second Dose Differ From an Equivalent First Dose?..... | 34 |
| IV. CONCLUSIONS..... | 35 |
| APPENDIXES | |
| A. Self Checklist | 37 |
| B. Numerical Facility Test..... | 38 |
| C. Aerosol Protocol | 39 |
| D. Abramson Checklist..... | 40 |
| E. Behavior Checklist..... | 45 |

UNCLASSIFIED

CONFIDENTIAL

(C) THE HUMAN ASSESSMENT OF EA 1729 AND
EA 3528 BY THE INHALATION ROUTE (U)

I. (C) INTRODUCTION.

(C) This report summarizes the results of recent investigations by the Psychopharmacology Branch of the Clinical Research Division into the aerosol effectiveness of EA 1729 and EA 3528, the free base and maleate forms, respectively, of d-lysergic acid diethylamide (LSD25).

(U) LSD25 has been well known to pharmacologists for more than 20 years as the most potent of all psychochemicals. Because of its interest to clinicians as well as research scientists, it has been extensively used and studied.

(U) In small doses (about 0.5 $\mu\text{g}/\text{kg}$, orally), effects are generally noted within half an hour and persist for at least 4 to 8 hr. The following features are commonly observed or described:

1. Euphoria, giggling.
2. Increased nervous tension, restlessness.
3. Increased sensitivity to minor stimuli.
4. Distractability, indecisiveness.
5. Feelings of strangeness, unreality.
6. Passivity, indifference.

(U) Larger doses (1 to 2 $\mu\text{g}/\text{kg}$, orally) cause more profound effects, detectable within 15 min and disappearing for the most part after about 12 hr. These may include:

1. Loss of control over thoughts and inability to focus attention.
2. Marked feelings of unreality, strangeness, detachment, altered identity.
3. Perceptual distortions: fluctuations in apparent size, shape, color, distance, and texture of surfaces; hyperacusis, synesthesia, kaleidoscopic imagery, hallucinations.

CONFIDENTIAL

CONFIDENTIAL

4. Disturbances in body image, feelings of electricity, "butterflies," abdominal spasms, pressure in head and chest, coldness, trembling, changes in size, shape, or consistency of body parts, etc.

5. Various "secondary" symptoms: paranoid suspiciousness, delusions, outbursts of hostility, sudden assaultiveness, muteness, immobility, pacing, laughter, sobbing, etc.

(C) In a series of field trials in 1958, volunteers at Fort Bragg, N. C., were assigned a variety of team missions to be carried out after the ingestion of 150 μg /man of LSD25. These tasks included reporting of meteorological information, fire direction control, artillery control surveying, and anti-aircraft tracking. In these cases, the dose given resulted in loss of effectiveness sufficient to constitute failure in the mission, as judged by XVIII Airborne Corps evaluation teams.

(C) In the 1961 report,* summarizing the results of these and other clinical studies of the effectiveness of LSD25, the author concluded that incapacitation by the oral route could be achieved with doses as low as 1 μg /kg.

(C) In 1963, a variety of preliminary studies on LSD25 (including the free base various salts**) were resumed with the ultimate aim of establishing the aerosol effectiveness of this agent. The following initial conclusions were reached:

1. Both the maleate and the free base were effective aerosols but it was not possible to say which, if either, was superior.† The maleate sometimes induced coughing.

* (U) Sim, Van M. CRDLR 3074. Clinical Investigation of EA 1729 (U). June 1961. SECRET Report.

** (C) EA 1729: free base of LSD25; EA 1653: tartrate salt; and EA 3528: maleate salt.

† (C) To facilitate comparison of effectiveness of the various forms of LSD, it was decided to express the dose in terms of the free base, which has a molecular weight of 323. Since the tartrate (EA 1653) and the maleate (EA 3528) salts have formula weights of 430 and 439, respectively, doses of either salt must be multiplied by 0.74 or 0.75 to convert them to the free base equivalent.

CONFIDENTIAL

CONFIDENTIAL

2. Plasma levels of LSD25 could be measured reliably and used as a basis for comparing absorption of various forms of the drug by different routes of administration. The performance and plasma level values of an intravenous study (figure 1) were later used in effectiveness comparisons with the inhalation route.

3. The degree of response was related positively to both the aerosol retained dose and the plasma level, but considerable variability was present among the individuals exposed to similar doses.

4. The aerosol retained dose and the plasma level were highly correlated, indicating that absorption is highly predictable from the retained dose (figure 2).

5. Further inhalation studies were required to provide sufficient observations to permit adequate statistical analysis of dose-response relationships.

(U) The final aerosol test series employed both free base and maleate. The data from these tests together with those already obtained during the preliminary test series were combined in an attempt to answer the following questions:

1. What are the ED 50 and the ECT 50 for these compounds by the inhalation route?
2. What are the onset times, peak times, and durations of action of these compounds when given by aerosol?
3. What are the estimated safety factors for these agents?
4. Is there any difference in potency between the free base and the maleate on a molecule-for-molecule basis?
5. Is the coughing tendency observed earlier with the maleate a consistent finding and does it have practical significance?
6. What is the relative potency of these agents when the inhalation, oral, and intravenous routes are compared?
7. Does the response to a second dose differ from the response to an equivalent first dose?

CONFIDENTIAL

CONFIDENTIAL




FIGURE 1

SERIAL PLASMA LEVELS EA 1653 VERSUS SERIAL PERFORMANCE SCORES (U)

(U) Each dot represents the mean value for five subjects receiving the tartrate iv. Dose was equivalent to $2.0 \mu\text{g}/\text{kg}$ of the free base. Plasma level is plotted against a log scale. Closed dots = plasma levels; open dots = percent numerical facility scores.

CONFIDENTIAL

CONFIDENTIAL




FIGURE 2

AEROSOL RETAINED DOSE VERSUS PLASMA LEVEL (U)

(U) Plasma levels are the means of samples taken at 1 and 2 hr following inhalation of EA 3528. Retained doses are expressed as free base equivalent.

CONFIDENTIAL

UNCLASSIFIED

(U) In keeping with the above expressed aims, the following features were included in the test plan for this series:

1. To provide a sufficient sample, there were to be 16 exposures to each form of the agent (table 1); however, for technical reasons a second exposure was not completed in two subjects.

2. To facilitate comparisons between maleate and free base, matched equivalent doses were used.

(U)

TABLE I

DESIGN FOR TEST SERIES

March-April 1964

| Name | Target dose | First dose | Second dose |
|------|-------------|------------|-------------|
| Joh | 2.0 | 2.0 F | 2.0 M |
| Rod | | 2.1 M | 2.5 F |
| Kra | | 2.1 M | 2.7 F |
| Pro | | 2.2 F | --- |
| Got | 3.0 | 3.0 F | 2.7 M |
| Hug | | 3.2 F | 3.5 M |
| Wai | | 3.5 M | 3.6 F |
| Ada | | 3.5 M | 3.7 F |
| Dar | 4.5 | 4.1 M | 4.0 F |
| Win | | 4.4 M | 4.1 F |
| Gol | | 4.5 F | 4.9 M |
| Hou | | 4.7 F | 4.9 M |
| Bat | 6.8 | 6.8 F | --- |
| Nee | | 6.9 F | 6.9 M |
| Hyt | | 7.1 M | 7.1 F |
| Nea | | 7.8 M | 7.6 F |

NOTE: Doses are retained doses in $\mu\text{g}/\text{kg}$, expressed as free base equivalent. M = maleate; F = free base. The second dose in each case was intended to equal the actual first dose, rather than the initial target dose.

UNCLASSIFIED

UNCLASSIFIED

3. To control response variability, each man was to be exposed twice, once to each form of the agent, with a 2-week interval between exposures; the second dose was to be matched to the first.

4. To avoid effects attributable to the order of exposure to the two forms of the agent, a counterbalanced design was employed.

5. To provide an adequate, but not excessively broad, dose range, there were four target doses: 2.0, 3.0, 4.5, and 6.8 μ g/kg, representing a logarithmic series with a constant increment of 50% between levels.

6. To establish a clinical criterion for effectiveness, a standardized brief interview was conducted at a specific time following exposure. This was rated in accordance with a specified rating system. "Effectiveness" does not imply military incapacitation.

7. To permit quantitative pharmacologic comparisons of free base and maleate, the plasma assay and the Numerical Facility (NF) substest of the Texas Battery were employed.

8. To reduce bias, a double-blind arrangement was followed so that the clinical rating was made without knowledge of dose or performance scores.

II. (U) METHODS.

A. Selection and Management of Volunteers.

1. Screening and Selection.

Sixteen subjects were selected from a group of 45 on the basis of a psychiatric interview. All had previously received a complete physical examination, laboratory studies, including an EEG and a Minnesota Multiphasic Personality Inventory, and an interview by the screening psychologist.

2. Briefing and Supervision.

Following selection, the 16 subjects were assembled and the program was explained to them in general terms. They were told there would be two aerosol tests and additional psychological and other test activities during the intervening and subsequent periods. All the men readily agreed to participate.

UNCLASSIFIED

UNCLASSIFIED

Arrangements were made for the members of the group to be assigned to the same set of squad rooms, and a senior Master Sergeant with extensive neuropsychiatric training and experience was assigned a room in the same area. Each individual was also assigned a specific partner from among his roommates with whom he would always be scheduled on any test he was to undergo. Liaison with NCO supervisor was facilitated by requiring each volunteer subject to complete a short checklist (appendix A) twice daily, the results of which were tabulated by the supervisor.

During the 6-week test period, biweekly meetings were scheduled with the psychiatrist, at which time the men were given an opportunity to learn of the progress of the study and to give their opinions about any aspect of the program.

B. Description of Measurements Used.

1. Clinical Rating of Severity.

A clinical rating of severity was developed, based upon the independent judgment of the two psychiatrists. A scale of 0-3, corresponding to no effect, mild, moderate, and severe, respectively, was employed. Although in all the aerosol series, a double-blind procedure was adhered to, both raters had access to all clinical information, including NF scores, during the preliminary series; however, it was decided that NF scores might influence the judgment of the raters and they were accordingly withheld during the later test series. Interrater reliability in both cases was approximately 0.80 by rank order correlation.

The following procedure was adhered to during the later series:

a. A standard interview was constructed, to be administered at 0105 experimental time by one of the two psychiatrists on the team. This interview, which normally required 5 to 8 min to complete, consisted of questions designed to bring out evidence of disorientation, difficulty in mental calculation, inattentiveness, loss of expressive fluency, disturbances in visual perception or in bodily sensations, and inability to reproduce a simple geometric pattern from memory. The interviews were recorded on videotape and rated at a convenient time later in the study.

b. In rating the interviews, primary drug effects were considered, rather than "secondary" behavioral features (such as paranoid ideation, depression, hostility, etc.). This distinction is based on an earlier study in which it was concluded the so-called primary effects are

UNCLASSIFIED

UNCLASSIFIED

dose related whereas the secondary phenomena are not.* The primary effects included an essential difficulty in directing the train of thought (i.e., in concentrating) and a distortion of visual perception (e.g., shifting, rolling or undulating appearance to the walls of the room). Bodily sensations of tension, tingling, trembling, and hypersensitivity, as well as distortions (changes in size, shape, texture, weight, or consistency of body parts), were also considered to be manifestations of primary drug effect. An overall rating, emphasizing the thinking difficulty, was assigned to each case, using the following rating scale:

| <u>Rating</u> | <u>Intensity of drug effect</u> |
|---------------|---------------------------------|
| 0 == | none |
| 0-1 = | barely discernible |
| 1 = | mild |
| 1-2 = | mild to moderate |
| 2 = | moderate |
| 2-3 = | moderate to severe |
| 3 = | severe |

Since two ratings were averaged in each case to produce a single rating, the following average ratings resulted:

| <u>Defined as not effective</u> | <u>Defined as effective</u> |
|---------------------------------|-----------------------------|
| 0.0 | 2.2 |
| 0.2 | 2.5 |
| 0.5 | 2.8 |
| 0.8 | 3.0 |
| 1.0 | |
| 1.2 | |
| 1.5 | |
| 1.8 | |
| 2.0 | |

* Klee, Gerald D., Bertino, Joseph, Weintraub, Walter, and Callaway, Enoch. The Influence of Varying Doses on the Effects of Lysergic Acid Diethylamide (LSD-25) In Humans, J. Nervous and Mental Disease 132:404 (1961).

UNCLASSIFIED

UNCLASSIFIED

c. Ratings of 2, 2 or higher were decided in advance to be indicative of an effective dose. It is important to note that the "effective" dose is not necessarily equivalent to the "incapacitating" dose. (To regard them as synonymous plainly requires some unusually broad assumptions.) "Effective" as used here arbitrarily means the effects are considered to be more than moderate in intensity by a crude clinical rating system.

d. By way of further clarification, the terms moderate and severe were intended to be applied as follows:

(1) Moderate Intensity (Rating of "2"). If the subject displays some slowing in his performance of serial subtraction (as compared with control performance) and makes several errors or hesitates for long periods in the middle of the task, he is considered to be showing moderate difficulty in thinking. In addition, there are usually definite alterations in visual perception (e. g., shimmering or oozing appearance to flat surfaces, fluctuations in light intensity, etc.). There may also be some changes in body image (e. g., feelings of lightness, tingling, coldness, increase in muscle tone, etc.).

(2) Severe Intensity (Rating of "3"). Serial subtraction is either impossible or only one or two subtractions are performed, with great effort and considerable delay, even with encouragement. If able to communicate the visual distortions he is experiencing, the subject will generally describe movements of an oscillatory type, with larger amplitude than that seen with lesser effects. His body may feel as if it is charged with electricity, about to burst; his stomach may be seized with intermittent nauseating contractions; and he may feel as if he is "in a fog," changing in size or shape or composition. Usually, he is only capable of brief phrases, which he repeats several times; or at times he can only nod, or smile in a perplexed manner, in response to questions. It may be noted that despite these profound effects subjects are not stuporous or disoriented.

2. Numerical Facility Test:

This is a speed-accuracy test in the performance of addition problems (see sample in appendix B) which are available in 20 forms of equal difficulty. The subject is given 3 min to complete as many problems as possible, and the score is the number of correct solutions divided by the baseline score, yielding a percentage. The baseline is calculated by taking the mean of the five highest scores of the ten baseline trials, which are obtained over a 2-day period prior to exposure. Because some slight practice effect continues to elevate subsequent scores, a new baseline (the mean of

UNCLASSIFIED

UNCLASSIFIED

the 5 highest scores from the original 10 and an additional 2 trials given just prior to the second exposure) is calculated for use during the second experiment. The scheduling of the NF test is shown on the Aerosol Protocol to be found in appendix C.

3. Abramson Checklist.

In the course of extensive investigations with LSD25, Abramson and his associates developed a list of symptoms commonly described by subjects.* He has indicated that low and high doses could be distinguished through the simple expedient of counting the number of positive replies given by the subject when questioned as to the presence or absence of each of 76 symptoms. A sample of the questionnaire form and the schedule followed in administering it are both to be found in appendix D. In actual use, with the nurse reading the questions to the subject and recording the positive replies, about 5 min are required for its completion.

4. Behavior Checklist.

This is a list of 27 behavioral signs, originally developed for BZ, but carried over to other agents for the purpose of comparison. The sample and schedule for use are shown in appendix E. To produce a single score, items that were assumed to reflect positive drug effects were given a plus sign and those that reflect absence of drug effect (i. e., indicate normal behavior) were assigned a minus sign. The summation of ratings for the 27 items (adding 6 for calibration) was used as a score in subsequent data analysis.

5. Behavioral Notes.

As in all psychochemical studies requiring nurses to be in attendance, frequent descriptive entries by the nurse in the clinical record are considered highly important. Four to six typewritten pages of such observations are generally collected in the course of a 24-hr study of this type.

* Abramson, H. A., Jarvik, M. E., Kaufman, M. R., Kornetsky, C., Levine, A., and Wagner, M. Lysergic Acid Diethylamide (LSD-25). I. Physiological and Perceptual Responses. *J. Psychol.* 39:3 (1955).

UNCLASSIFIED

UNCLASSIFIED

6. Draw-a-Man Test.

This is a 3-min procedure that has been included in many psychochemical studies during the past 3 years. A quantitative scoring system for these drawings is still undergoing development.

7. Heart Rate and Blood Pressure.

These measures are in the schedule primarily for safety purposes.

8. Pupil Size.

Various techniques for the recording of pupil size have been employed in previous studies within the Division, but none have proved entirely satisfactory. In this test series, a technique was introduced entailing the use of a binocular telescope with direct reading of pupil size from a millimeter scale positioned along the horizontal diameter of the pupil.

9. EEG Studies.

A single EEG was carried out at 0130 experimental time. Spontaneous activity and the effect of single flash and repetitive photic stimulation (photic driving) were compared with control records. The results of this study will be reported in a separate publication by the investigator responsible for this phase of the project.

10. Plasma Levels of Agent.

A 12-ml blood sample was taken at 0100 and 0200 hr experimental time. Bloods were centrifuged and plasma was removed and frozen. Plasma samples (5 ml) were later assayed according to a modification of Axelrod's spectrofluorometric method.* Details will be submitted in a separate report.

* Axelrod, Julius, Brady, Roscoe O., Witkop, Bernard, and Evarts, Edward V. The Distribution and Metabolism of Lysergic Acid Diethylamide. *Annals N. Y. Acad. Sciences* 66:435 (1957).

UNCLASSIFIED

UNCLASSIFIED

11. Neurological Measurement of Accommodation and Convergence.

The change in accommodative convergence ratios observed in preliminary studies with LSD25 was studied in this series in the hope that it would prove a sensitive indicator of dose. The results will be presented elsewhere by the investigator responsible for these studies.

C. Technique of Exposure.

Subjects were trained to breathe in conformity with a standard pattern that assured a rate of 15 breaths per minute and a minute volume of approximately 10 liters. The method, developed previously for BZ inhalation studies, employs an oscilloscopic display of the respiratory activity. The subject endeavors to make the beam track a prescribed curve of inspiration and expiration superimposed on the oscilloscope screen. Rate is established by sweep time of the beam. Vertical deflection is produced by air flow across a detector situated in the orifice of the face mask. With minimal practice, stable breathing patterns are easily achieved.

Because of the possibility that coughing might occur during inhalation, subjects were instructed in all cases that if the urge to cough occurred, they should in no case break contact with the mask, but cough into the system if necessary.

The agent, both maleate and free base, was generated as a water solution in droplet form; average particle size being 0.8μ . Concentration in air was usually less than $20\ \mu\text{g/liter}$, and exposure time from 1 to 4 min. Retention was calculated by direct measurement of concentration differences between inspired and expired air. This difference was multiplied by the total volume breathed. Drug retained in apparatus was then subtracted to give total retained dose per man.

D. Tabulation of Data.

Following the typing and collation of individual case records, selected information was abstracted from the records and entered on code sheets. After punch cards were prepared from these sheets, the cases were sorted in order of retained dose and certain columns of data were extracted in list form as shown in table 2. The cards were also used to prepare paper tape inputs for computer analysis. Complete analysis will require considerable time, and further statistical findings will be summarized in a future supplement to this report.

UNCLASSIFIED

UNCLASSIFIED

(U)

TABLE 4

ABSTRACTED NUMERICAL DATA FOR ALL 60 INHALATION EXPOSURES

| Case number | Name | Form of agent* | Retained dose | First or second exposure | Ct | Plasma level | | Score on numerical facility | | | | | Average clinical rating |
|-------------|------|----------------|---------------|--------------------------|----|--------------|--------|-----------------------------|------|------|------|------|-------------------------|
| | | | | | | 1 hour | 2 hour | Experimental time | | | | | |
| | | | | | | µg/liter | | 0050 | 0130 | 0200 | 0230 | 0330 | |
| | | | µg/kg | | | | | % | | | | | |
| 370 | Che | M | 0.3 | 1 | 03 | - | - | 090 | 090 | - | 092 | 086 | 0.0 |
| 358 | Bel | M | 1.3 | 1 | 15 | - | - | 099 | 099 | - | - | 105 | 1.0 |
| 361 | Lur | M | 1.4 | 1 | 10 | - | - | 084 | 093 | - | 066 | 094 | 1.5 |
| 366 | Bro | M | 1.7 | 1 | 20 | - | - | 029 | 045 | - | 062 | 045 | 2.0 |
| 359 | Del | M | 1.9 | 1 | 17 | - | - | 081 | 090 | - | 073 | 075 | 1.0 |
| 367 | Fen | M | 1.9 | 1 | 19 | - | - | 084 | 041 | - | 069 | 071 | 2.0 |
| 468 | Joh | F | 2.0 | 1 | 20 | 1.5 | 0.0 | 052 | 078 | - | 048 | 072 | 1.0 |
| 482 | Joh | F | 2.0 | 2 | 18 | 1.7 | 0.8 | 056 | 064 | 060 | 076 | 084 | 1.0 |
| 421 | Hef | F | 2.0 | 1 | 15 | 1.4 | 0.7 | 092 | 066 | - | 082 | 076 | 1.0 |
| 470 | Rod | M | 2.1 | 1 | 22 | 1.1 | 1.2 | 072 | 089 | 085 | 093 | 085 | 1.5 |
| 460 | Kra | M | 2.1 | 1 | 2 | 1.2 | 1.0 | 072 | 056 | 066 | 093 | 064 | 2.0 |
| 458 | Pro | F | 2.2 | 1 | 7 | 1.3 | 1.4 | 096 | 054 | 060 | 071 | 065 | 0.8 |
| 423 | Cox | F | 2.3 | 1 | 25 | 1.2 | 1.2 | 056 | 058 | - | 052 | 054 | 2.2 |
| 484 | Rod | F | 2.5 | 2 | 28 | 1.8 | 1.8 | 086 | 076 | 083 | 086 | 086 | 1.5 |
| 363 | Spr | M | 2.6 | 1 | 24 | - | - | 049 | 069 | - | 049 | 047 | 2.2 |
| 473 | Kra | F | 2.7 | 2 | 22 | 1.6 | 0.5 | 069 | 086 | 083 | 083 | 084 | 1.0 |
| 472 | Col | M | 2.7 | 2 | 29 | 1.2 | 0.3 | 079 | 063 | 056 | 079 | 087 | 2.2 |
| 362 | Mcp | M | 2.7 | 1 | 33 | - | - | 056 | 040 | - | 065 | 062 | 2.2 |
| 456 | Col | F | 3.0 | 1 | 33 | 0.8 | 0.7 | 071 | 071 | 079 | 063 | 085 | 0.8 |
| 394 | Stu | F | 3.1 | 1 | 31 | - | - | 032 | 032 | - | - | 060 | 3.0 |
| 466 | Hug | F | 3.2 | 1 | 3' | 1.5 | 1.0 | 079 | 092 | 082 | 088 | 085 | 1.8 |
| 462 | Whi | M | 3.5 | 1 | 3 | .3 | 1.0 | 070 | 037 | 089 | 089 | 092 | 2.0 |
| 479 | Hug | M | 3.5 | 2 | 3 | .0 | 1.2 | 066 | 083 | 117 | 092 | 101 | 2.0 |
| 463 | Ada | M | 3.5 | 1 | 26 | 2.5 | 2.5 | 043 | 050 | 069 | 071 | 087 | 1.2 |
| 476 | Whi | F | 3.6 | 2 | 40 | 1.4 | 0.9 | 050 | 054 | 061 | 079 | 086 | 1.2 |
| 365 | Smi | M | 3.6 | 1 | 41 | - | - | 069 | 065 | - | 085 | 081 | 1.0 |
| 475 | Ada | F | 3.7 | 2 | 37 | 1.6 | 1.8 | 078 | 067 | 072 | 074 | 085 | 2.0 |
| 364 | Ino | M | 3.8 | 1 | 41 | - | - | 078 | 087 | - | 092 | 100 | 1.0 |
| 369 | Has | M | 3.8 | 1 | 55 | - | - | 038 | 031 | - | 035 | 063 | 2.0 |
| 474 | Dar | F | 4.0 | 2 | 41 | 1.7 | 1.8 | 093 | 093 | 090 | 110 | 097 | 0.9 |
| 478 | Win | F | 4.1 | 2 | 52 | 1.9 | 0.9 | 042 | 036 | 056 | 044 | 072 | 2.2 |
| 459 | Dar | M | 4.1 | 1 | 19 | 2.7 | 2.1 | 067 | 070 | 077 | 080 | 094 | 1.5 |
| 371 | Thr | M | 4.1 | 1 | 33 | - | - | 081 | 100 | - | 066 | 026 | 2.2 |
| 395 | Tho | F | 4.1 | 1 | 40 | - | - | 028 | 011 | - | 000 | 006 | 4.5 |
| 368 | Foj | M | 4.2 | 1 | 47 | - | - | 058 | 048 | - | 055 | 069 | 2.0 |
| 464 | Win | M | 4.4 | 1 | 43 | 1.4 | 1.7 | 031 | 030 | 044 | 036 | 056 | 2.5 |
| 455 | Col | F | 4.5 | 1 | 35 | 1.8 | 0.9 | 068 | 057 | 060 | 053 | 063 | 1.2 |
| 422 | Whi | F | 4.5 | 1 | 44 | 3.1 | 2.3 | 053 | 045 | - | 066 | 069 | 1.5 |
| 360 | Kea | M | 4.5 | 1 | 23 | - | - | 000 | 004 | - | 009 | 024 | 3.0 |
| 465 | Hou | F | 4.7 | 1 | 32 | 2.3 | 1.5 | 064 | 068 | 064 | 062 | 067 | 1.2 |
| 480 | Hou | M | 4.9 | 2 | 33 | 2.5 | 2.5 | 092 | 084 | 089 | 080 | 106 | 1.2 |
| 471 | Col | M | 4.9 | 2 | 53 | 3.0 | 2.7 | 068 | 040 | 035 | 045 | 043 | 2.0 |
| 428 | Mor | F | 4.9 | 1 | 30 | 3.6 | 2.9 | 038 | 040 | - | 070 | 04 | 1.8 |
| 372 | And | M | 5.0 | 1 | 64 | - | - | 054 | 038 | - | 056 | 056 | 2.0 |
| 396 | Tro | F | 5.0 | 1 | 50 | - | - | 049 | 069 | - | 077 | 074 | 2.0 |
| 426 | Woo | F | 5.1 | 1 | 35 | 2.2 | 1.5 | 069 | 065 | - | 059 | 084 | 2.0 |
| 373 | Osh | M | 5.3 | 1 | 64 | - | - | 060 | 054 | - | 038 | 076 | 2.0 |
| 393 | Sou | F | 6.0 | 1 | 74 | - | - | 055 | 000 | - | 025 | 055 | 3.0 |
| 427 | Jon | F | 6.4 | 1 | 56 | 5.3 | 4.8 | 000 | 000 | - | 000 | 000 | 3.0 |
| 430 | Rup | F | 6.4 | 1 | 66 | 4.7 | 4.2 | 047 | 002 | - | 042 | 042 | 2.8 |
| 425 | Whe | F | 6.6 | 1 | 71 | 3.5 | 3.1 | 000 | 008 | - | 000 | 020 | 3.0 |
| 457 | Bat | F | 6.8 | 1 | 65 | 3.0 | 1.8 | 000 | 004 | 037 | 000 | 015 | 2.8 |
| 467 | Nee | F | 6.9 | 1 | 58 | 2.0 | 1.2 | 745 | 047 | 053 | 072 | 090 | 2.0 |
| 481 | Nee | M | 6.9 | 2 | 69 | 3.3 | 2.5 | 048 | 012 | 033 | 042 | 029 | 2.5 |
| 424 | Hyt | F | 7.0 | 1 | 65 | 4.2 | 3.9 | 068 | 059 | - | 062 | 066 | 2.5 |
| 477 | Hyt | F | 7.1 | 2 | 64 | 5.9 | 4.4 | 020 | 008 | 034 | 026 | 034 | 3.0 |
| 461 | Hyt | M | 7.1 | 1 | 62 | 3.2 | 2.2 | 000 | 009 | 012 | 003 | 015 | 3.0 |
| 429 | Rel | F | 7.6 | 1 | 64 | 6.0 | 4.5 | 009 | 012 | - | 029 | 077 | 2.0 |
| 469 | Nea | M | 7.8 | 1 | 74 | 4.4 | 2.8 | 017 | 023 | 032 | 038 | 049 | 1.8 |
| 483 | Nea | F | 7.6 | 2 | 74 | 6.2 | 3.4 | 001 | 028 | 031 | 030 | 052 | 2.5 |

* M = maleate; F = free base. Retained dose is in µg/kg, expressed as free base equivalent.

UNCLASSIFIED

CONFIDENTIAL

III. (C) RESULTS.

(U) The results are presented and discussed in terms of the specific questions raised at the initiation of this study.

A. (C) What is the ED50 and the ECT50 for LSD25 by the Inhalation Route?

As shown in tables 3 and 4, the estimated values (expressed as free base equivalent) are as follows:

ED50 = 5.8 μ g/kg
(95% confidence limits: 2.5 to 13.5)

ECT50 = 55 mg min/cu m
(95% confidence limits: 34 to 90)

(Because of the greater formula weight of the maleate salt, the ED50 and ECT50 for it would be 7.7 μ g/kg and 73 mg min/cu m, respectively.)

The effective dose, based on a clinical rating as defined in the Methods Section, cannot be equated with military incapacitation. Effective was defined here only to mean greater than moderate clinical drug effect.

B. (C) What are the Onset Times, Peak Times, and Durations of Action of the Effective Inhalation Dose?

Onset time is defined here as that time at which performance on the NF test fell below 75% of baseline. Clinically, this represents definite impairment in mental efficiency.

Employing this criterion, the onset time for the effective dose may be interpolated to approximately 15 min (figure 3). Peak time is about 1-1/2 hr. Partial recovery time (time at which scores return to 75% or higher) is about 5-1/2 hr, and "full" recovery time (100% or higher) is between 8 and 12 hr.

As shown in figure 1, the half-life of the drug following intravenous injection is about 3 hr. The percent decrease from 1 to 2 hr is 22%. In the inhalation cases, blood levels were measured at 1 and 2 hr, and with the maleate, the blood level dropped an average of 23% from the first to the second hour, while the average decrease for the free base was 23%. This would indicate a half-life of 155 and 130 min, respectively, for the maleate and the free base. It seems unlikely that the half-life for the free base would be

CONFIDENTIAL

UNCLASSIFIED

TABLE 3

PROBIT ANALYSIS OF EFFECTIVE DOSE

| Mean dose* | Responses |
|------------|-----------|
| 1.67 | 0/10 |
| 2.59 | 5/10 |
| 3.62 | 0/10 |
| 4.32 | 5/10 |
| 5.39 | 3/10 |
| 7.16 | 7/10 |

Criterion: clinical rating
2.2 or higher

Solution: **

Slope = 2.52

Standard error of slope
= 0.94

ED50 = 5.8 (2.5 to 13.5)

* All doses are retained dose in μ g/kg of free base equivalent.

** Bliss method used for statistical solution.

TABLE 4

PROBIT ANALYSIS OF EFFECTIVE CT

| Mean Ct* | Responses |
|----------|-----------|
| 14.6 | 0/10 |
| 20.1 | 3/10 |
| 33.8 | 3/10 |
| 41.1 | 3/10 |
| 56.3 | 4/10 |
| 68.6 | 7/10 |

Criterion: clinical rating
2.2 or higher

Solution: **

Slope = 2.42

Standard error of slope
= 0.83


ECT50 = 55 (34 to 90)

* All doses are expressed as concentration x time (milligrams per cubic meter x minutes of exposure.) Minute volumes are 10 liters/min.

** The Bliss method is used for statistical solution.

UNCLASSIFIED

UNCLASSIFIED



FIGURE

THE EFFECT OF DOSE ON SERIAL NUMERICAL FACILITY PERFORMANCE

Dose values are mean retained doses ($\mu\text{g}/\text{kg}$) expressed as free base equivalent. Each dose group consists of 7 to 8 subjects. Points plotted represent median scores for each group.

UNCLASSIFIED

CONFIDENTIAL

shorter by the inhalation route than the intravenous route, and it may well be that these differences are not significant. Also, it should be noted that a half-life estimate based on only two times of measurement is not fully acceptable, since there is no assurance that equilibration has been completed. If a compromise figure of 150 min is used, the prediction would be that less than 10% of the original blood concentration at the time of equilibration would remain at 10 hr. This corresponds to the time of nearly "complete" recovery (100% on NF) from effects (figure 4).

C. (C) What is the Estimated Safety Factor for the Agent?

The safety factor for an incapacitating agent has been defined as the ratio between the LD1 and the ED50. Since no direct information is available concerning the lethality of the compound in man, it is difficult to assume a value for the LD50 and, of course, the LD1 is unknown.

With the exception of the rabbit, all animal species tested have demonstrated unusually high lethal to effective ratios; as high as several thousand in the monkey. If man has a toxicological response to this agent similar to most animals then there would be a wide margin of safety.

D. (C) Is There Any Difference in Potency Between the Free Base and the Maleate on a Molecule-for-Molecule Basis?

None of the comparisons made in this study reveal any distinct differences between the two forms of LSD25 as far as potency is concerned. As can be seen in figures 4, 5, 6, and 7, the distribution of maleate response is completely overlapping with those for the free base. No consistent tendency for one form to show greater correlations between dose and response variables is discernible (table 5). The average dose/plasma level ratios for the two forms are virtually identical, as shown in table 6.

A comparison of the NF scores and blood levels at 1 hr for the maleate exposures with those for the free base (using only those 14 cases that were exposed to both forms in nearly equal dosage) reveals no difference of any consequence (table 7).

Thus, all the evidence so far examined indicates that if one allows for differences in formula weight, the free base and the maleate are equally effective by the inhalation route.

CONFIDENTIAL

CONFIDENTIAL




FIGURE 4

RETAINED DOSE VERSUS CT (U)

(U) Both retained doses and Ct values are expressed in terms of free base equivalent. Black dots = maleate; white dots = free base.

CONFIDENTIAL

CONFIDENTIAL




FIGURE 5

RETAINED DOSE VERSUS CLINICAL RATING OF SEVERITY (U)

(U) Retained doses are expressed in terms of free base equivalent.
Black dots = maleate; white dots = free base.

CONFIDENTIAL

CONFIDENTIAL




FIGURE 6

RETAINED DOSE VERSUS PLASMA LEVEL (U)

(U) Plasma levels are the mean of the 1- and 2-hr values. Retained dose is expressed as free base equivalent. Black dots = maleate; white dots = free base.

CONFIDENTIAL

CONFIDENTIAL




FIGURE 7

RETAINED DOSE VERSUS NUMERICAL FACILITY (U)

(U) Retained doses are expressed as free base equivalent. Percentage scores represent the mean of the 0130 and 0230 scores for each individual. Black dots = maleate; white dots = free base.

CONFIDENTIAL

CONFIDENTIAL

(C)

TABLE 5

CORRELATIONS (U)

| | Maleate | Free base |
|--|---------|-----------|
| Retained dose versus: | | |
| 1. Ct | 0.95** | 0.94** |
| 2. Plasma level (1 hr) | 0.88** | 0.80** |
| 3. Plasma level (2 hr) | 0.77* | 0.69* |
| 4. Numerical facility, % (0050) | -0.64 | -0.80** |
| 5. Numerical facility, % (0130) | -0.75* | -0.68* |
| 6. Numerical facility, % (0205) | -0.62 | -0.83** |
| 7. Numerical facility, % (0230) | -0.81** | -0.63* |
| 8. Numerical facility, % (0325) | -0.67* | -0.59 |
| 9. Pupil size (0045) | -0.09 | -0.11 |
| 10. Pupil size (0120) | 0.48 | 0.36 |
| 11. Pupil size (0220) | 0.12 | 0.05 |
| 12. Pupil size (0320) | -0.01 | -0.11 |
| 13. Heart rate (0045) | 0.42 | 0.39 |
| 14. Heart rate (0120) | 0.58 | 0.51 |
| 15. Heart rate (0220) | 0.29 | 0.57 |
| 16. Heart rate (0320) | 0.53 | 0.28 |
| 17. Behavior check list (0030) | 0.57 | 0.62* |
| 18. Behavior check list (0125) | 0.70* | 0.38 |
| 19. Abramson check list (0040) | 0.15 | 0.11 |
| 20. Abramson check list (0125) | 0.24 | 0.22 |
| 21. Abramson check list (0225) | 0.49 | -0.03 |
| 22. EEG severity | 0.21 | -0.11 |
| 23. Accommodative convergence ratio change | 0.64 | -0.16 |
| 24. Clinical severity rating | 0.48 | 0.78** |

Note: (U) Except for items 22 and 23, the number of subjects = 14 for the maleate and 16 for the free base. A single asterisk indicates significance at the 0.01 level, two asterisks indicates the 0.001 level.

CONFIDENTIAL

CONFIDENTIAL

(C)

TABLE 6

COMPARISON OF PLASMA LEVELS (0100) AND NUMERICAL FACILITY SCORES (0050) AT EQUIVALENT DOSES OF MALEATE AND FREE BASE (U)

| Mean dose | EA 3528 (maleate) | | EA 1729 (free base) | |
|-------------------------|----------------------|--------------|------------------------|--------------|
| | Numerical facility | Plasma level | Numerical facility | Plasma level |
| $\mu\text{g}/\text{kg}$ | % | ng/ml | % | ng/ml |
| 2.2 | 56 | 1.7 | 52 | 1.5 |
| | 72 | 1.1 | 86 | 1.8 |
| | 72 | 1.2 | 69 | 1.6 |
| 3.3 | 79 | 1.2 | 71 | 0.8 |
| | 86 | 2.0 | 79 | 1.5 |
| | 70 | 1.3 | 50 | 1.4 |
| | 43 | 2.5 | 78 | 1.6 |
| 4.4 | 67 | 2.7 | 93 | 1.7 |
| | 31 | 1.4 | 42 | 1.9 |
| | 68 | 3.0 | 68 | 1.8 |
| | 92 | 2.5 | 64 | 2.3 |
| 7.2 | 48 | 3.3 | 45 | 2.0 |
| | 0 | 3.2 | 20 | 5.9 |
| | 17 | 4.4 | 1 | 6.2 |
| Means: | 57.2 | 2.25 | 58.4 | 2.28 |

CONFIDENTIAL

CONFIDENTIAL

(C)

TABLE 7

COMPARISON OF RATIOS (RETAINED DOSE/PLASMA LEVEL) AT
VARIOUS DOSE LEVELS OF MALEATE AND FREE BASE (U)

| EA 3528 (maleate) | | | | EA 1729 (free base) | | | |
|--------------------|------------------|-------------------|-------|---------------------|------------------|-------------------|-------|
| Number of subjects | Mean dose | Mean plasma level | Ratio | Number of subjects | Mean dose | Mean plasma level | Ratio |
| | $\mu\text{g/kg}$ | ng/ml | | | $\mu\text{g/kg}$ | ng/ml | |
| 5 | 2.5 | 1.4 | 1.8 | 5 | 2.2 | 1.1 | 2.0 |
| | | | | 5 | 3.9 | 1.4 | 2.8 |
| 4 | 4.1 | 1.7 | 2.4 | 6 | 4.0 | 1.9 | 2.1 |
| | | | | 5 | 6.4 | 3.7 | 1.7 |
| 5 | 6.2 | 2.9 | 2.1 | 5 | 6.9 | 3.7 | 1.9 |
| Mean ratio = 2.1 | | | | Mean ratio = 2.1 | | | |

NOTE: (U) . Administered by inhalation route. Doses are expressed as free base equivalent. Plasma levels are the mean values of the 1- and 2-hr determinations.

CONFIDENTIAL

CONFIDENTIAL

E. (C) Is the Coughing Tendency Observed Earlier With the Maleate a Consistent Finding and Does It Have Practical Significance?

The answer to this question would appear to be no, at least not at the concentrations used in this study. Two subjects out of 14 did cough in the presence of the maleate aerosol, while none of those exposed to the free base displayed this symptom. A few others reported a mildly irritating sensation in the throat. This was confirmed by one of the investigators who took several breaths of the same concentration that elicited the coughing and noted a dust-like sensation in the back of the throat. The concentration of agent that caused both instances of coughing was the highest used in the entire series (approximately 20 $\mu\text{g}/\text{liter}$). It is, therefore, possible that some coughing would be produced if the agent were disseminated at higher concentrations; however, this may not be of any great practical importance because the two subjects who coughed were able to continue breathing the aerosol and had the usual retention of the drug.

F. (U) What is the Relative Effectiveness of the Inhalation Route, Compared to the Oral and Intravenous Routes?

1. Oral Versus Aerosol: Figure 8 illustrates the method used to estimate the ratio of effectiveness for these two routes. NF percent scores at 1.5 and 2.5 hr following exposure were averaged for each subject, and the subjects were grouped according to dose. The mean score for each group was plotted and a linear relationship was observed between dose and response values. The ratio between the slopes of the best fitting lines is defined to be the effectiveness ratio. This ratio is approximately 3.75.

2. Intravenous Versus Aerosol: Figure 9 shows a similar technique again applied to the NF percent scores. Only one intravenous dose group of five subjects was available. The same subjects, however, were also exposed to the same material by the inhalation route. The small sample size is, therefore, partially compensated for by the elimination of most of the sampling error. One hundred percent performance of NF at a dose of 0.0 is assumed to anchor one end of a linear regression line. The ratio of the slopes here is 3.9.

In figure 10, an alternative calculation is shown, based on the plasma levels plotted against dose in the same cases. The ratio obtained by this method is 3.7.

On the basis of these ratios, it seems probable that the oral and intravenous routes are roughly equal in effectiveness, and the inhalation route is 25% to 30% as effective as either.

CONFIDENTIAL




FIGURE 8

METHOD OF ESTIMATING RELATIVE EFFECTIVENESS OF ORAL VERSUS AEROSOL ROUTE BY NUMERICAL FACILITY

Aerosol scores represent medians for 6 groups of 10 subjects each. Each subject's score is the mean of 0130 and 0230 scores, regardless of route. Aerosol doses are retained doses expressed as free base equivalent. Oral doses are also expressed as free base equivalent. Oral scores represent medians for 4 groups containing 4, 4, 13, and 7 subjects, respectively.




FIGURE 9
METHOD OF ESTIMATING RELATIVE EFFECTIVENESS OF IV VERSUS
AEROSOL ROUTE BY NUMERICAL FACILITY SCORES

The white dot represents the mean percent score for 5 subjects who received 2.0 $\mu\text{g}/\text{kg}$ of free base iv. The black dot represents mean score for the same 5 subjects who received a mean retained dose of 6.0 $\mu\text{g}/\text{kg}$ free base. A linear dose response regression line is assumed from the previous figure's demonstration of linearity in the case of the oral and aerosol routes.





FIGURE 10
METHOD OF ESTIMATING RELATIVE EFFECTIVENESS OF IV VERSUS
AEROSOL ROUTE BY PLASMA LEVELS

The white dot represents the mean plasma level for 5 subjects exposed to a mean aerosol retained dose of 6.0 µg/kg of the free base. Each subject's plasma level, in turn, represents the mean of the 1- and 2-hr values. The black dot represents the mean plasma level (similarly determined) for the same 5 subjects after exposure to 2.0 µg/kg of the tartrate (in free base equivalent) by the iv route. A linear regression line passing through the origin is assumed from previously demonstrated linear relationship between dose and blood level (see figure 7).

UNCLASSIFIED

G. (U) Does the Response to a Second Dose Differ From an Equivalent First Dose?

Figure 11 shows no apparent differences in NF percent scores for the 14 subjects who were each exposed to the agent on two occasions.



RETAINED DOSE VERSUS NUMERICAL FACILITY
COMPARISON BETWEEN FIRST AND SECOND DOSE EFFECTS

Retained doses are expressed as free base equivalent.
White dots = first exposures; black dots = second exposures.

CONFIDENTIAL

IV. (C) CONCLUSIONS.

The ED50 for EA 1729 by the inhalation route is 5.8 (2.5 to 13.5) $\mu\text{g}/\text{kg}$ retained dose. The ECT50 is 55 (34 to 90) $\text{mg min}/\text{cu m}$, calculated at a minute volume of 10 liters. The ED50 and ECT50 for the maleate salt would be 1/3 greater on a formula weight basis, i. e., 7.7 $\mu\text{g}/\text{kg}$ and 73 $\text{mg min}/\text{cu m}$, respectively.

Onset time for the effective aerosol dose is about 15 min, peak time about 1-1/2 hr, and partial recovery time about 5-1/2 hr. Full recovery requires at least 12 hr.

The safety factor in man cannot be stated with certainty. If man resembles most other animals in his toxicological response, the ratio of lethal to effective dose would be very high; however, there is no direct information about lethality in man.

If a correction is made for differences in formula weight, the effectiveness of the maleate and free base forms of the agent by inhalation is roughly the same.

There is a tendency to cough during inhalation of the maleate at higher concentrations, but in the few instances in which this occurred, there was no change in the retained dose.

By the aerosol dissemination technique employed, it was shown that the effectiveness of the aerosol route is 0.25 to 0.30 that of the oral or intravenous routes.

Prior exposure to the agent does not significantly influence the numerical facility performance decrement observed when an equivalent dose is given 2 weeks later.

CONFIDENTIAL

UNCLASSIFIED

(U)

APPENDIX A

SELF CHECKLIST

Name []

Date []

Day: S M T W T F S

A. M. Items:

- 1. Hours of sleep last night: _____
- 2. Last night I slept: _____
 - a. Less soundly than usual
 - b. As soundly as usual
 - c. More soundly than usual
- 3. Last night I dreamed: _____
 - a. Not at all
 - b. Occasionally
 - c. Frequently
- 4. Today I feel: _____
 - a. Tired
 - b. Normally rested
 - c. Full of pep
- 5. I think today will be: _____
 - a. One of my bad days
 - b. An average day
 - c. One of my good days

P. M. Items:

- 6. Today the time seemed to pass: _____
 - a. Slowly
 - b. At the usual pace
 - c. Quickly
- 7. In general it was: _____
 - a. One of my bad days
 - b. An average day
 - c. One of my good days
- 8. The things I did were: _____
 - a. Pretty boring
 - b. Routine with a few high spots
 - c. Quite interesting
- 9. Right now I'm: _____
 - a. Quite tired
 - b. Not really tired
 - c. Full of pep
- 10. During the day I found I was: _____
 - a. Very relaxed
 - b. Quite keyed up and jittery
 - c. Somewhere in between

COMMENT:

(This part is optional. Write down anything you think may interest the research staff.)

(Use other side if necessary)

UNCLASSIFIED

UNCLASSIFIED

APPENDIX B

NUMERICAL FACILITY TEST

Form NF-6

Copyright by Hogg Foundation for Mental Health, 1999

| | | | | | | | | | |
|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
| 66 | 14 | 68 | 20 | 64 | 5 | 7 | 66 | 14 | 17 |
| 67 | 90 | 5 | 46 | 19 | 26 | 97 | 71 | 65 | 53 |
| 40 | 84 | 51 | 78 | 58 | 93 | 10 | 86 | 52 | 77 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 73 | 97 | 70 | 88 | 85 | 68 | 58 | 21 | 55 | 56 |
| 14 | 11 | 90 | 79 | 60 | 23 | 85 | 74 | 71 | 19 |
| 64 | 75 | 33 | 97 | 15 | 22 | 9 | 54 | 87 | 71 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 5 | 73 | 96 | 51 | 6 | 35 | 98 | 87 | 37 | 59 |
| 71 | 88 | 2 | 40 | 15 | 85 | 42 | 66 | 78 | 36 |
| 95 | 5 | 74 | 14 | 93 | 15 | 99 | 47 | 22 | 50 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 86 | 90 | 19 | 2 | 20 | 13 | 64 | 54 | 41 | 72 |
| 11 | 52 | 7 | 4 | 1 | 92 | 61 | 73 | 26 | 12 |
| 5 | 27 | 60 | 2 | 90 | 3 | 71 | 32 | 78 | 41 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 65 | 41 | 62 | 33 | 10 | 51 | 62 | 98 | 63 | 94 |
| 9 | 14 | 93 | 31 | 75 | 59 | 99 | 11 | 6 | 96 |
| 68 | 86 | 55 | 8 | 6 | 77 | 6 | 12 | 55 | 26 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 76 | 22 | 59 | 39 | 40 | 59 | 51 | 44 | 13 | 44 |
| 83 | 98 | 33 | 54 | 78 | 56 | 29 | 95 | 8 | 95 |
| 20 | 12 | 82 | 16 | 78 | 78 | 16 | 92 | 27 | 27 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 37 | 22 | 43 | 49 | 89 | 6 | 93 | 63 | 1 | 36 |
| 90 | 8 | 90 | 36 | 62 | 83 | 15 | 16 | 50 | 99 |
| 53 | 51 | 35 | 37 | 93 | 2 | 49 | 84 | 18 | 79 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 81 | 86 | 91 | 71 | 56 | 96 | 83 | 60 | 17 | 69 |
| 13 | 68 | 29 | 95 | 83 | 45 | 48 | 62 | 88 | 61 |
| 29 | 32 | 70 | 67 | 13 | 8 | 43 | 71 | 30 | 10 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |
| 39 | 92 | 13 | 13 | 27 | 64 | 36 | 46 | 71 | 78 |
| 35 | 33 | 80 | 20 | 92 | 13 | 92 | 40 | 44 | 71 |
| 1 | 98 | 3 | 2 | 79 | 5 | 88 | 80 | 91 | 32 |
| <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> | <input type="text"/> |

Subject _____ Examiner _____ Date _____

UNCLASSIFIED

UNCLASSIFIED

(U)

APPENDIX C

AEROSOL PROTOCOL

| Real Time | Exp. Time | Check* | Procedure |
|-----------|-----------|--------|---------------------------------------|
| | 0010 | | S. C. L. (Symptom Check-List) (1) |
| | 0015 | | NF (Numerical Facility) |
| | 0020 | | HR and PS (Heart Rate and Pupil Size) |
| | 0030 | | B. C. L. (Behavior Check-List) |
| | 0040 | | S. C. L. (2) |
| | 0045 | | HR and PS |
| | 0050 | | D. A. M. (Draw-A-Man) and NF |
| | 0100 | | Draw Blood |
| | 0105 | | TV Interview |
| | 0120 | | HR and PS |
| | 0125 | | S. C. L. (3) |
| | 0130 | | D. A. M. and NF |
| | 0135 | | EEG and B. C. L. |
| | 0200 | | Draw Blood |
| | 0205 | | NF |
| | 0220 | | HR and PS |
| | 0225 | | S. C. L. (4) |
| | 0230 | | D. A. M. and NF |
| | 0240 | | TV Interview (B. C. L.) |
| | 0320 | | HR and PS |
| | 0325 | | NF |
| | 0450 | | HR and PS |
| | 0455 | | S. C. L. (5) |
| | 0500 | | D. A. M. and NF |
| | 0510 | | B. C. L. |
| | 0650 | | HR and PS |
| | 0655 | | S. C. L. (6) |
| | 0700 | | D. A. M. and NF |
| | 0710 | | B. C. L. |
| | 0850 | | HR and PS |
| | 0900 | | NF |
| | 1220 | | HR and PS |
| | 1225 | | S. C. L. (7) |
| | 1230 | | D. A. M. and NF |
| | 1720 | | HR and PS |
| | 1730 | | NF |
| | 2220 | | HR and PS |
| | 2230 | | NF |
| | 2300 | | Write Personal Account of Test |
| | 2400 | | Complete Check List |

* Check when completed.

UNCLASSIFIED

UNCLASSIFIED

(U)

APPENDIX D

ABRAMSON CHECKLIST

| Subject _____ | Dosage _____ | Date _____ | Experimental Time: | | | | | |
|---|--------------|------------|--------------------|------|------|------|------|------|
| | | | 0010 | 0040 | 0125 | 0225 | 0455 | 0655 |
| 1. Do you feel ill in any way? | | | | | | | | |
| 2. Are you nauseated? | | | | | | | | |
| 3. Have you a feeling of choking? | | | | | | | | |
| 4. Is salivation increased? | | | | | | | | |
| 5. Or decreased? | | | | | | | | |
| 6. Is your appetite increased? | | | | | | | | |
| 7. Or decreased? | | | | | | | | |
| 8. Do you have a dry taste in your mouth? | | | | | | | | |
| 9. Do you have a funny taste in your mouth? | | | | | | | | |
| 10. Is it a bitter taste? | | | | | | | | |
| 11. Are your lips numb? | | | | | | | | |
| 12. Or drawn back as if you were smiling? | | | | | | | | |
| 13. Does your head ache? | | | | | | | | |
| 14. Are things moving about you? | | | | | | | | |
| 15. Do you feel dizzy? | | | | | | | | |
| 16. Or unsteady? | | | | | | | | |
| 17. Is there difficulty in breathing? | | | | | | | | |

UNCLASSIFIED

UNCLASSIFIED

APPENDIX D (contd)

| | | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|
| 18. Have you passed more urine than usual? | | | | | | | | | |
| 19. Are you aware of your heartbeat? | | | | | | | | | |
| 20. Is it faster than usual? | | | | | | | | | |
| 21. Are you sweating? | | | | | | | | | |
| 22. Are you hot? | | | | | | | | | |
| 23. Or cold? | | | | | | | | | |
| 24. Are you palms moist? | | | | | | | | | |
| 25. Or dry? | | | | | | | | | |
| 26. Or cold? | | | | | | | | | |
| 27. Is your skin sensitive? | | | | | | | | | |
| 28. Do you have funny feelings on your skin? | | | | | | | | | |
| 29. Do your hands and feet feel peculiar? | | | | | | | | | |
| 30. Do they feel heavy? | | | | | | | | | |
| 31. Or light? | | | | | | | | | |
| 32. Is there pressure in your ears? | | | | | | | | | |
| 33. Is your hearing abnormal? | | | | | | | | | |
| 34. Is it more acute than usual? | | | | | | | | | |
| 35. Is your eyesight blurred? | | | | | | | | | |
| 36. Do you have difficulty in focusing your vision? | | | | | | | | | |
| 37. Do you see double? | | | | | | | | | |

UNCLASSIFIED

UNCLASSIFIED

APPENDIX D (contd)

| | | | | | | | | |
|--|--|--|--|--|--|--|--|--|
| 38. Are shapes and colors altered in any way? | | | | | | | | |
| 39. Does light bother you? | | | | | | | | |
| 40. Do things seem too close? | | | | | | | | |
| 41. Or too far away? | | | | | | | | |
| 42. Do you tremble inside? | | | | | | | | |
| 43. Do you feel weak? | | | | | | | | |
| 44. Or fatigued? | | | | | | | | |
| 45. Do you feel drowsy? | | | | | | | | |
| 46. Do you feel as if in a dream? | | | | | | | | |
| 47. Are you anxious? | | | | | | | | |
| 48. Do you tremble outside? | | | | | | | | |
| 49. Are you nervous? | | | | | | | | |
| 50. Are you afraid? | | | | | | | | |
| 51. Do you feel confused? | | | | | | | | |
| 52. Do you feel different since you have had the medicine? | | | | | | | | |
| 53. Do you see any lights with your eyes closed? | | | | | | | | |
| 54. Do people appear to be larger? | | | | | | | | |
| 55. Do people appear to be smaller? | | | | | | | | |
| 56. Do you see any colors with your eyes closed? | | | | | | | | |

UNCLASSIFIED

UNCLASSIFIED

APPENDIX D (contd)

| | | | | | | | |
|---|--|--|--|--|--|--|--|
| 57. Do things appear to move nearer and closer as you watch them? | | | | | | | |
| 58. Do your hands feel clumsy? | | | | | | | |
| 59. Do you feel nappy? | | | | | | | |
| 60. Do you feel sad? | | | | | | | |
| 61. Do you feel bored? | | | | | | | |
| 62. Do questions bother you? | | | | | | | |
| 63. Do you want to be alone? | | | | | | | |
| 64. Do you want to be with people? | | | | | | | |
| 65. Do you feel the medicine? | | | | | | | |
| 66. Is the feeling from the medicine stronger? | | | | | | | |
| 67. Is the feeling from the medicine weaker? | | | | | | | |
| 68. Is it hard to concentrate? | | | | | | | |
| 69. Do you have pains in the stomach? | | | | | | | |
| 70. Have you felt that you need to move your bowels? | | | | | | | |
| 71. Do your hands and feet change size as you look at them? | | | | | | | |
| 72. Do your hands and feet change shape as you look at them? | | | | | | | |
| 73. Do your hands and feet change color as you look at them? | | | | | | | |

UNCLASSIFIED

UNCLASSIFIED

APPENDIX D (contd)

| | | | | | | | | |
|---|--|--|--|--|--|--|--|--|
| 74. Do you feel that your hands, feet or any other part of your body is no longer a part? | | | | | | | | |
| 75. Have you seen any colors on the wall? | | | | | | | | |
| 76. Have you seen things like a fantastic Walt Disney movie? | | | | | | | | |

UNCLASSIFIED

UNCLASSIFIED

APPENDIX E

BEHAVIOR CHECK LIST

NAME _____ DATE _____
 SERIAL NUMBER _____ PAGE _____

| | REAL TIME | EXPR. TIME | | | | | | |
|-------------------------------------|-----------|------------|--|--|--|--|--|--|
| Mostly asleep or lying down | | | | | | | | |
| Quite restless and active | | | | | | | | |
| Picking at specks or clothing | | | | | | | | |
| Exploring walls | | | | | | | | |
| Can obey simple request | | | | | | | | |
| Speaks without being spoken to | | | | | | | | |
| Pleasant and friendly | | | | | | | | |
| Suspicious, cautious, hesitant | | | | | | | | |
| Negativistic, irritable, or hostile | | | | | | | | |
| Makes comments of paranoid nature | | | | | | | | |
| Interested in TV, magazines, etc | | | | | | | | |
| Hallucinating | | | | | | | | |
| Speech is nonsensical at times | | | | | | | | |
| Confabulates | | | | | | | | |
| Seems quite normal | | | | | | | | |
| Short attention span | | | | | | | | |
| Confused as to place | | | | | | | | |
| Confused as to time and date | | | | | | | | |
| Confused as to person | | | | | | | | |
| Impaired recent memory | | | | | | | | |
| Tends to stumble | | | | | | | | |
| Poor coordination | | | | | | | | |
| Tends to undress | | | | | | | | |
| Cannot button clothing | | | | | | | | |
| Complains about vision | | | | | | | | |
| Complains of dry mouth | | | | | | | | |
| Complains of weakness in legs | | | | | | | | |

SMUA Form 6-81
 24 Jul 63

UNCLASSIFIED

CONFIDENTIAL

ABSTRACT

1. ORIGINATING ACTIVITY - U. S. Army Edgewood Arsenal Chemical Research and Development Laboratories, Edgewood Arsenal, Maryland - Clinical Research Division.
- 2a. REPORT SECURITY CLASSIFICATION - CONFIDENTIAL
- 2b. GROUP - GROUP 4, DOWNGRADED AT 3 YEAR INTERVALS;
DECLASSIFIED AFTER 12 YEARS
3. REPORT TITLE - THE HUMAN ASSESSMENT OF EA 1729 AND
EA 3528 BY THE INHALATION ROUTE (U)
4. DESCRIPTIVE NOTES - The work was started in March 1963 and
completed in April 1964
5. AUTHORS - Ketchum, James S., Aghajanian, George K., Bing,
Oscar H. L.
6. REPORT DATE - July 1964
- 7a. TOTAL NO. OF PAGES - 45
- 7b. NO. OF REFS. - 4
- 8a. CONTRACT OR GRANT NO. -
- 8b. PROJECT NO. - Project 1C522301A079
- 8c. TASK NO. -
- 9a. ORIGINATORS REPORT NO. - CRDLR 3226
- 9b. OTHER REPORT NO(S). -
10. AVAILABILITY/LIMITATION NOTICES - Qualified requesters may
obtain copies of this report from Headquarters, Defense Documen-
tation Center, ATTN: TISIA-2, Cameron Station, Alexandria,
Virginia
11. SUPPLEMENTARY NOTES - Nondefense medical aspects of
chemical agents (U)
12. SPONSORING ACTIVITY -

CONFIDENTIAL

CONFIDENTIAL

13. ABSTRACT

(C) This report summarizes the results of recent investigations, by the Psychopharmacology Branch of the Clinical Research Division, into the aerosol effectiveness of EA 1729 and EA 3528. The ED50 for EA 1729 by inhalation is 5.8 µg/kg retained dose. The ECT50 is 55 mg/min, and the ED50 and ECT50 for EA 1653 is one third greater, because of the weight of the maleate. On a molecule-for-molecule basis, EA 1729 and EA 1653 are equally potent. Onset time for the effective dose is 15 min, peak time 1-1/2 hr, and partial recovery time about 5-1/2 hr. The effectiveness of the aerosol route appears to be about 0.25 to 0.30 that of the oral or intravenous routes.

14. KEYWORDS

Incapacitation
Effectiveness
Plasma levels
Retained dose
Hallucinations
Numerical facility test
Clinical rating
Human assessments
Psychopharmacology
EA 1729
EA 3528
EA 1653
Inhalation
ED50
ECT50
Toxicological response
Dissemination
Chemical agents
LSD25

CONFIDENTIAL